Kamal Adawi, M.S., MBA

Kamal Adawi, M.S., MBA

Chief Financial Officer and TreasureratFate Therapeutics· In the 2025 proxy

Pay in FY2025Fate Therapeutics stock -40.4% the same year

Kamal Adawi, M.S., MBA was paid $714.8K in FY2025 (Dec). Fate Therapeutics stock fell 40.4% that year.

Pay$100 in the stock at the end of FY24 → $60
Pay is from the Summary Compensation Table of each Fate Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Fate TherapeuticsPublic company · 1 yr
    • Chief Financial Officer and Treasurer2025 – Present · 1 yrStock in role +31%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?